Form 4: Spruce Biosciences Director, Kirk Ways, Acquires 30,000 Stock Options

Director Kirk Ways acquired 30,000 stock options in Spruce Biosciences, Inc. on May 22, 2024, according to a Form 4 filing.

Summary

• Kirk Ways, a director of Spruce Biosciences, Inc., acquired 30,000 stock options on May 22, 2024.
• The exercise price of these options is $0.7511.
• The options vest on the first anniversary of the grant date or fully on the date of the company's 2025 annual stockholder meeting, subject to continuous service.
• The options will also vest in full upon a Change in Control as defined in the 2020 Equity Incentive Plan.
• The expiration date for these options is May 21, 2034.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard insider transaction disclosure. The acquisition of options could be seen as a slightly positive signal, but it's not a major event.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders (officers, directors, or those holding more than 10% of a company's shares) buy or sell stock in their own company. These filings provide transparency to the market regarding insider transactions.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment.

Key Dates